About

There are major unaddressed issues in Alzheimer’s Disease clinical practice such as:

• Identifying accessible fluid biomarker to determine time for reaching amyloid negativity to know when to stop treatment
• Understanding impact of disease state on functional outcome
• Understanding impact of baseline tau load on functional outcome

We use a combination of a mechanistic Quantitative Systems Pharmacology (QSP) model of amyloid aggregation with a computational neuroscience model, calibrated on functional scales with symptomatic treatments to understand these unaddressed clinical issues.